期刊
ONCOTARGET
卷 7, 期 37, 页码 59727-59741出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.10847
关键词
myeloma; bortezomib; heat shock; HSF1
资金
- Emory Proteomics Core and Cancer Tissue and Pathology Shared Resource of the Winship Cancer Institute of Emory University [R01 CA127910, P30 CA138292]
- TJ Martell Foundation
Proteasome inhibitors such as bortezomib are highly active in multiple myeloma by affecting signaling cascades and leading to a toxic buildup of misfolded proteins. Bortezomib-treated cells activate the cytoprotective heat shock response (HSR), including upregulation of heat shock proteins (HSPs). Here we inhibited the bortezomib-induced HSR by silencing its master regulator, Heat Shock Factor 1 (HSF1). HSF1 silencing led to bortezomib sensitization. In contrast, silencing of individual and combination HSPs, except HSP40 beta, did not result in significant bortezomib sensitization. However, HSP40 beta did not entirely account for increased bortezomib sensitivity upon HSF1 silencing. To determine the mechanism of HSF1 activation, we assessed phosphorylation and observed bortezomib-inducible phosphorylation in cell lines and patient samples. We determined that this bortezomib-inducible event is phosphorylation at serine 326. Prior clinical use of HSP inhibitors in combination with bortezomib has been disappointing in multiple myeloma therapy. Our results provide a rationale for targeting HSF1 activation in combination with bortezomib to enhance multiple myeloma treatment efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据